Other languages AVROBIO, Inc.

Equities

AVRO

US05455M1009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
1.2 ^USD	-3.23%		-5.51%	-11.76%

Mar. 21	North American Morning Briefing : Investors -2-	DJ
Mar. 14	AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Sector Update: Health Care Stocks Slipping Late Wednesday	23-07-12
Sector Update: Health Care Stocks Softer in Afternoon Trading	23-07-12
AVROBIO Says Exploring Strategic Alternatives to Boost Shareholder Value; Shares Jump	23-07-12
Avrobio to Conduct Exploration of Strategic Alternatives	23-07-12
AVROBIO Completes Sale of Gene Therapy Program to Novartis for $87.5 Million	23-06-12
Novartis Pharma AG and Novartis Pharmaceuticals Corporation completed the acquisition of Cystinosis Gene Therapy Program from AVROBIO, Inc..	23-06-08
Sector Update: Health Care Stocks Slightly Higher Late Monday	23-05-22
Sector Update: Health Care Stocks Advancing Monday Afternoon	23-05-22
AVROBIO to Sell Cystinosis Gene Therapy Program to Novartis for $87.5 Million	23-05-22
AVROBIO, Inc. Enters into an Asset Purchase Agreement with Novartis Pharma AG and Novartis Pharmaceuticals Corporation	23-05-22
Avrobio Says Gene Therapy Candidate Showed Durable Treatment Effect in Phase 1/2 Trial	23-05-18
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
AVROBIO, Inc. Announces Resignation of Geoff Mackay as President	23-05-02
AVROBIO, Inc. Announces CEO Changes	23-05-02
AVROBIO Appoints Erik Ostrowski as Interim Chief Executive	23-05-01
AVROBIO, Inc. Auditor Raises 'Going Concern' Doubt	23-03-22
Avrobio Reports 'Positive' Interim Data in Gaucher Disease Trial, Plans Phase 2/3 Study Next Year	22-12-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AVROBIO, Inc.

Equities

AVRO

US05455M1009

Other languages

Filters